Physician profile
Chhan Touch
NPI 1194792408
$6,024.79
in general payments reported to CMS, 2019-2025
23 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $636 · 2023: $964 · 2024: $1,454 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599 · Education: $24.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,599.20 |
| Education | $24.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.75 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $869.63 | 2022-2025 | |
| Novo Nordisk INC | $794.77 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $588.09 | 2022-2025 | Repatha, Prolia, Evenity |
| Abbvie INC. | $539.77 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $298.46 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $266.13 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $260.58 | 2025 | Rezdiffra |
| Lundbeck LLC | $232.35 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $183.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $183.04 | 2021 | |
| Gilead Sciences, INC. | $158.73 | 2022-2024 | |
| Pfizer INC. | $125.22 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $108.29 | 2021 | |
| Ardelyx, INC. | $98.02 | 2024-2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $81.07 | 2021-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $54.35 | 2021-2022 | |
| Astellas Pharma US INC | $52.53 | 2021-2024 | Veozah |
| Corcept Therapeutics | $35.21 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.74 | 2025 | Jardiance |
| Lucid Diagnostics INC. | $19.18 | 2025 | |
| Echosens North America, INC. | $15.39 | 2024 | Fibroscan |
| Abbott Laboratories | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhan Touch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.